| Methods |
3‐week washout period; 4‐week placebo run‐in; inclusion criteria= sitting DBP 90‐115 mm Hg and SBP </= 200 mm Hg during run‐in; 8‐week double‐blind treatment, dosage of enalapril doubled after 4 weeks of treatment if DBP >/= 85 mm Hg |
| Participants |
Enalapril 10 mg: n=40(28 males,12 females); mean age=58.8(9.5) years; baseline SBP=165(15) mm Hg, DBP=92(7.8) mm Hg, HR=81.2(13.3) bpm;
Placebo: n=41(26 males,15 females); mean age=61.9(7.8) years; baseline SBP=166(18) mm Hg, DBP=93(8.2) mm Hg, HR=81.2(14.3) bpm |
| Interventions |
Enalapril 10 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Trough sitting SBP/DBP using automated device (Dinamap);
WDAE |
| Notes |
Used week 4 BP data only; BP change and SD of change not reported; endpoint BP and SD reported; imputed endpoint SD for SD of change; position of BP measurement not reported but likely sitting; BP data from Figure 1, p. 693; Jadad score=4; funding source= Bayer |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
